Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECT-001-Expanded Cord Blood Transplantation in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
NCT04990323Phase 2Completed
- Sponsor
- ExCellThera
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of dorocubicel in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), mixed phenotype acute leukemia (MPAL), juvenile myelomonocytic leukemia (JMML), sponsored by ExCellThera. Started Dec 2021; status: completed.
02
Drugs
dorocubicel
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)mixed phenotype acute leukemia (MPAL)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT04990323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990323.